|
|
|
|
|
|
|
|
|
|
|
|
|
03.03.26 - 22:06
|
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 (Business Wire)
|
|
|
Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year
Delivered GAAP Operating Income of $4.2 Million for the Fourth Quarter; Non-GAAP Operating Income of $7.1 Million for Q4 2025, Above Prior Guidance Range
Full-Year GAAP Operating Expenses of $229.8 Million in 2025; Non-GAAP Operating Expense of $209.7 Million, Within the Company's Guidance Range of $208 Million to $213 Million, with Second Half 2025 Expenses Declining 4% Compared to the First Half, Driving Meaningful Year-Over-Year Operating Leverage in the Second Half
2026 Net Revenue Guidance of $327 Million to $337 Million, Which Represents 10% to 13% Growth from 2025 Results
2026 Non-GAAP Operating Expense Guidance Reflects Meaningful Operating Leverage, With Only 0% to 3% Year-Over-Year Growth Resulting in a Range of $210 Million to $216 Million; Company Expects to Achieve a Low- to Mid-Single Digit Adjusted EBITDA Margin in 2026
NEWPORT BEACH, C...
|
|
|
|
|
|
|
17.02.26 - 14:06
|
Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13758456. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (NASDA...
|
|
|
13.02.26 - 22:09
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218 restricted stock units (RSUs) and 34,952 stock options of the company's common stock to 36 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with grant dates and vesting commencement dates ranging from December 7, 2025 through February 7, 2026, as inducements material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs and options vest 25% on each annual anniversary of the vesting commencement date. The stock options have an exercise price equal to the closing price of the company's common stock on the last business day prior to the applicab...
|
|
|
|
|
09.01.26 - 14:36
|
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue (Business Wire)
|
|
|
Provides 2026 Net Revenue Guidance and Maintains Projection for Full-Year 2026 Profitability1
Preliminary Unaudited Net Revenue of $88.6 Million to $90.6 Million for the Fourth Quarter 2025, Representing 12% to 15% Growth Over the Prior Year; Company Reaffirms an Important Milestone of Positive Non-GAAP Operating Income of $5 Million to $7 Million for Q4 2025
Preliminary Unaudited Net Revenue of $295.5 Million to $297.5 Million for the Full-Year 2025, Representing 11% to 12% Growth Over the Prior Year
2026 Net Revenue Guidance of $327.0 Million to $337.0 Million, Which Represents 11% to 13% Growth from Preliminary Unaudited 2025 Results; Company Remains on Track to Achieve Sustainable Annual Profitability1 Beginning in 2026
Updates 2028 Long-Term Financial Outlook to Reflect Total Net Revenue of $450 Million to $500 Million, Representing a Three-Year CAGR of 15% to 19%, and Non-GAAP Operating Income Margins of 13% to 15% for 2028
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a globa...
|
|
|
|
|
|
|
14.11.25 - 22:06
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus 2023 Inducement Incentive Plan, with a grant and vesting commencement date of November 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $6.56 per share, the closing price of the company's common stock on November 7, 2025. The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option v...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
